Floatz logo

rd14-01

Diffuse Large B-cell Lymphoma

He HuangEarly Phase 1Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
73/ 100

Competitive context

28 Active assets in the Diffuse Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Mwanasha Merrill, MD
Phase 4BB
Tucidinostat
Rong Tao
Phase 3BB
Tafasitamab
Brown University
Phase 3BB
Everolimus
University of California, Davis
Phase 3BB
Tislelizumab
The First Affiliated Hospital with Nanjing Medical University
Phase 3BB

View all 50 →

Same molecule, other indications

rd14-01 is also rated in:

neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Mantle Cell LymphomaDormant
C
Indicative ·
34 / 100
View asset →
Follicular LymphomaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →